Table 2.

Baseline characteristics of matched groups according to mean arterial pressure reduction in the intensive treatment group: <20, 20 to <40, and ≥40 mm Hg

VariablesIntensive <20 mm Hg, n=1046Matched Standard, n=1046Intensive 20 to <40 mm Hg, n=1752Matched Standard, n=1752Intensive ≥40 mm Hg, n=286Matched Standard, n=286
Age, yr67±967±967±967±964±964±9
Cardiovascular disease, %191918182222
Women, %343234333637
Black race, %353432303941
No. of antihypertensive  agents1.8±1.01.8±1.01.7±1.01.7±1.01.6±1.11.7±1.1
Body mass index, kg/m229.9±5.730.0±5.730.1±5.830.1±5.830.3±6.330.0±5.8
eGFR, ml/min  per 1.73 m281±1581±1581±1682±1682±1782±16
Urinary albumin to  creatinine, mg/g7.7 (5.0–14.8)7.8 (5.0–15.1)9.0 (5.6–17.7)8.9 (5.6–17.7)12.1 (7.0–26.9)12.1 (6.4–28.6)
Fasting total  cholesterol, mg/dl189±43189±41193±40191±39204±47202±42
Fasting HDL  cholesterol, mg/dl52±1452±1553±1453±1555±1655±16
Fasting total  triglycerides, mg/dl104 (75–140)108 (77–153)107 (76–151)106 (78–157)111.5 (79–168)108 (76–160)
Fasting plasma  glucose, mg/dl100±14100±1599±1399±13100±1799±13
Statin use, %414441423233
Aspirin use, %515050504444
Current smoker, %151514142426
Baseline BP, mm Hg
  • Baseline clinical characteristics of the Systolic Blood Pressure Intervention Trial participants without CKD, including participants assigned to intensive BP control and propensity score–matched participants assigned to standard BP control. The group of patients in the intensive treatment group who attained each mean arterial pressure reduction category was matched with patients in the standard treatment group with similar baseline characteristics according to a propensity score. The following baseline covariates were included: age, sex, black race, smoking status, cardiovascular disease (clinical or subclinical), number of antihypertensive agents, statin and aspirin, ratio of urinary albumin to creatinine, systolic BP, diastolic BP, eGFR, glucose, total cholesterol, HDL, and triglycerides.